Source: CureToday articles
Treatment with Perjeta, Herceptin and chemotherapy post-surgery led to a significant overall survival benefit in HER2-positive early-stage breast cancer.
Recent Content
- Understanding the Unique Task of Treating Older Patients With Breast Cancer
- Community Behavioral Health Clinics Can Be Instrumental in Switching Patients to Long-Acting Injectable Antipsychotics
- I Found Strength After Surviving Multiple Myeloma and Through Recovery
- Mild to Moderate Adverse Events Possible in Pediatric Patients With Primary Immunodeficiency Receiving IVIG
- Custom-Made Vaccine Combo Proves Effective in Bladder Cancer
- Research Suggests Natural Supplementation Could Decrease Biological Age
- Pharmacist Spotlight: Juliana Chan, PharmD, FCCP, BCACP
- May 2025 Pharmacy Policy
- Perjeta Regimen Improves Survival in HER2+ Early-Stage Breast Cancer
- Leveraging AI Within Rare Disease Care While Maintaining Humanity